Press Releases

Date Title and Summary Additional Formats
Toggle Summary Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function View HTML
Toggle Summary American Journal of Psychiatry Publishes Minerva Neurosciences' MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia
WALTHAM, Mass. , July 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that the American Journal of Psychiatry has published online
View HTML
Toggle Summary Dr. Remy Luthringer, Minerva President and Chief Scientific Officer, to Present at CNS Summit View HTML
Toggle Summary Mark S. Levine Joins Minerva Neurosciences as VP and General Counsel View HTML
Toggle Summary Minerva Achieves Enrollment Target in Phase IIb Trial With MIN-101
WALTHAM, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it has met its enrollment target of 234 patients in
View HTML
Toggle Summary Minerva Announces Amended Agreement for MIN-202 in Insomnia
WALTHAM, Mass. , May 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it has entered into a binding term sheet to amend its co-development and license agreement with Janssen Pharmaceutica NV (Janssen) related to MIN-202 (JNJ 42827922)
View HTML
Toggle Summary Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia
WALTHAM, Mass. , June 22, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the successful completion of a bridging trial to select an improved, gastric-resistant (GR) formulation of MIN-101.
View HTML
Toggle Summary Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA View HTML
Toggle Summary Minerva Neurosciences Announces $15 Million Debt Facility With Oxford Finance LLC and Silicon Valley Bank
Funding supports Minerva continuing to advance the clinical program for MIN-101, the company's investigational compound in development for treatment of schizophrenia
View HTML
Toggle Summary Minerva Neurosciences Announces $31 Million Financing View HTML